Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Strong LLY News Boosts Active Healthcare ETF GDOC

BY | ETF Database
07/08/2026 | 20 VIEWS
Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios. At the same time, biotech and healthcare technology stocks stand to gain immensely from innovation, whether driven by AI or other breakthroughs. A prime example is the active healthcare ETF, GDOC, which recently got a major boost from positive news surrounding its largest holding, Eli Lilly (LLY).Key Takeaways: Positive news for LLY boosted the outlook for active healthcare ETF (GDOC B-) this week. The fund has recently performed well and saw its underlying data produce a momentum shift. Active management and potential tailwinds — such as future interest rate cuts —  could further bolster its outlook. JPMorgan raised its price target for Eli Lilly (LLY) this week, boosting an already strong month-and-a-half run for the active healthcare ETF. GDOC has returned 11.8% over the last three months, according to ETF Database data. This follows a period of underperformance at the start of 2026. What’s more, the fund’s price has risen above its 50-day Simple Moving Average (SMA), an indicator of its healthy momentum.What Active Health Care ETF GDOC Can DoThe Goldman Sachs Future Health Care Equity ETF (GDOC B-) charges a 75 basis point fee for its approach. The strategy actively invests in equities of firms driving global innovation in healthcare. Using a fundamental research-driven approach, GDOC looks for companies developing new treatments and technology in areas like genomics, precision medicine, and digital healthcare. Its active remit includes the flexibility to use futures, forwards, and options to meet its goals. GDOC will also see its fifth year of operation this Fall. All factors combined, the strategy is well-positioned for a strong second half. Should, for example, rates fall as the Strait of Hormuz reopens and the global economy improves, healthcare stocks also stand to benefit. This shift could bolster M&A activity, This shift could also spur M&A activity, providing an additional tailwind for the fund’s performance See more: Income ETF GPIQ Crosses $5 Billion in AUM Ahead of Key Milestone LLY’s positive news has given GDOC a lift, but what other stocks are driving its momentum? Johnson & Johnson (JNJ), its second-largest holding, has returned nearly 30% year to date. JNJ also just received approval from the FDA for a new cardiac catheter, the latest tool from its medical technology division. Looking ahead, GDOC stands to offer a strong thematic addition to growth-oriented portfolios. For more news, information, and strategy, visit the Future ETFs Content Hub.

More Commentary

Electrification Surge Fuels Case for Clean Energy ETF ACES
BY | ETF Database
5:12 am ET 07/09/26 | 16 VIEWS
REX Drone ETF Sees Inflows as Defense Spending Climbs
BY | ETF Database
7:19 am ET 07/09/26 | 8 VIEWS
Harnessing Consensus & Momentum: Defiance Debuts RANK ETF
BY | ETF Database
5:26 am ET 07/09/26 | 16 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.